GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Subscribe To Our Newsletter & Stay Updated